Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities—AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM

ConclusionsThe high ORR and reasonable duration of response could allow for potentially curative allogeneic hematopoietic cell transplantation for these patients with high-risk AML. Our initial data suggest that lenalidomide plus HMA is a promising approach for patients with AML with inv(3).
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 24 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Bimatshu Pyakuryal, Prasun Pudasainee, Venkat Rajasurya, Krishna Gundabolu, Vijaya Raj BhattAbstractProspective evidence for management of therapy-related acute myeloid leukemia (t-AML) is limited, with evidence extrapolated from major AML trials. Optimal treatment is challenging and needs consideration of patient-specific, disease-specific, and therapy-specific factors. Clinical trials are recommended, especially for unfit patients or those with unfavorable cytogenetics or mutations. CPX-351 as an up...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Elizabeth Lyden, Andrea Lee, Joel Michalski, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj BhattAbstractBackgroundThe role of obesity in prognosis of acute myeloid leukemia(AML) is debatable. Our retrospective study aimed to determine the effect of obesity on overall survival(OS) in AML.MethodsAML patients diagnosed at University of Nebraska Medical Center were divided into 3-groups based on body mass index (BMI): normal(18.5-25kg/m2) or underweight(
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSION: All tested biosimilars demonstrated similar effectiveness and safety profiles in patients with hematological tumors undergoing PBSC mobilization; therefore, they can be used interchangeably. PMID: 31663634 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Clin Apher Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackgroundThe optimal the conditioning regimens for allogeneic hematopoietic stem-cell transplantation, especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1562 myeloablative conditioning and 2693 nonmyeloablative conditioning groups, the ove...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rafiye Ciftciler, Haluk Demiroglu, Ibrahim Celalettin Haznedaroglu, Nilgun Sayınalp, Salih Aksu, Osman Ozcebe, Hakan Goker, Muruvvet Seda Aydın, Yahya BuyukasıkAbstractBackgroundThe majority of patients with acute myeloid leukemia (AML) receive intensive induction chemotherapy for obtaining a complete remission (CR). Despite consolidation chemotherapy and advances in allogeneic hematopoietic stem cell transplantation, most of these patients finally relapse and die from AML. The aim of this study is to determine the ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackground/AimThe optimal the conditioning regimens for allogeneic hematopoietic stem cell transplantation (HSCT), especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4,255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1,562 myeloablative conditioning (MAC) and 2,693 non-myeloablative conditi...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rafiye Ciftciler, Haluk Demiroglu, Ibrahim Celalettin Haznedaroglu, Nilgun Sayınalp, Salih Aksu, Osman Ozcebe, Hakan Goker, Muruvvet Seda Aydın, Yahya BuyukasıkAbstractBackground and AimThe majority of patients with acute myeloid leukemia (AML) receive intensive induction chemotherapy for obtaining a complete remission (CR). Despite consolidation chemotherapy and advances in allogeneic hematopoietic stem cell transplantation (alloHSCT), most of these patients finally relapse and die from AML. The aim of this study i...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 May 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Diego Adrianzen Herrera, Noah Kornblum, Olga Derman, Lizamarie Bachier-Rodriguez, R. Alejandro Sica, Aditi Shastri, Murali Janakiram, Amit Verma, Ira Braunschweig, Ioannis MantzarisAbstractIntroductionIn the United States, autologous hematopoietic cell transplantation (autoHCT) has fallen out of favor over chemotherapy consolidation for non–high-risk acute myeloid leukemia (AML) when allogeneic hematopoietic cell transplantation (alloHCT) is unfeasible, which is common in racial minorities because of donor registry ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOur results, despite low patient numbers, indicate that IDH mutations are associated with higher relapse rate after alloHCT. Further prospective studies on post transplantation IDH inhibition is required to improve outcomes in AML patients who carry IDH mutations.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 May 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Diego Adrianzen Herrera, Noah Kornblum, Olga Derman, Lizamarie Bachier-Rodriguez, R. Alejandro Sica, Aditi Shastri, Murali Janakiram, Amit Verma, Ira Braunschweig, Ioannis MantzarisAbstractIntroductionIn the United States, autologous hematopoietic cell transplantation (autoHCT) has fallen out of favor over chemotherapy consolidation for non-high-risk acute myeloid leukemia (AML) when allogeneic HCT (alloHCT) is unfeasible, which is common in racial minorities due to donor registry underrepresentation and socioeconomic cha...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Genetics | Leukemia | Lymphoma | Myeloma | Revlimid | Study | Transplants